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Transforming growth factor-b1 (TGF-b1), a tumour suppressing as well as tumour-promoting cytokine, is stored as an extracellular
matrix-bound latent complex. We examined TGF-b1 activation and localisation of TGF-b1 activity in gastric cancer. Gastric tumours
showed increased stromal and epithelial total TGF-b1 staining by immunohistochemistry. Active TGF-b1 was present in malignant
epithelial cells, but most strongly in smooth muscle actin expressing fibroblasts. Normal gastric mucosa from the same patient showed
some staining for total, and little for active TGF-b1. Active TGF-b1 levels were determined by ELISA on tissue homogenates,
confirming a strong increase in active TGF-b1 in tumours compared to corresponding normal mucosa. Moreover, high tumour TGF-
b1 activity levels were significantly associated with clinical parameters, including worse survival of the patients. Total and active TGF-
b1 levels were not correlated, suggesting a specific activation process. Of the different proteases tested, active TGF-b1 levels were
only correlated with urokinase activity levels. The correlation with urokinase activity suggests a role for plasmin in TGF-b1 activation in
the tumour microenvironment, resulting in transformation of resident fibroblasts to tumour promoting myofibroblasts. In conclusion
we have shown localisation and clinical relevance of TGF-b1 activity levels in gastric cancer.
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Transforming growth factor-b (TGF-b) is a multifunctional
cytokine, which influences cell differentiation, proliferation,
motility and apoptosis (Akhurst and Derynck, 2001; Elliott and
Blobe, 2005). Among the TGF-b family, which comprises TGF-b1,
-b2 and -b3, TGF-b1 is most abundantly expressed, especially in
various pathological conditions including chronic inflammatory
diseases (Marek et al, 2002) and cancer (Tsushima et al, 1996;
Akhurst and Derynck, 2001; Elliott and Blobe, 2005; Bierie and
Moses, 2006). Transforming growth factor-b1 has been shown
to reduce the immune response (Beck et al, 2001), stimulate angio-
genesis (Choi et al, 1997; Derynck et al, 2001; Bertolino et al, 2005),
increase synthesis of proteolytic enzymes (Seomun et al, 2001; Kim
et al, 2004) and stimulate extra cellular matrix (ECM) deposition
(Cheng and Lovett, 2003) in the tumour microenvironment.
Several studies examined the role of TGF-b1 in gastric cancer.
Studies on TGF-b1 mRNA showed expression in both normal and
tumour tissue, but levels in gastric tumours were strongly
upregulated (Naef et al, 1997; Park et al, 2002). Immunohisto-
chemical studies showed TGF-b expression in tumour cells (Naef
et al, 1997; Park et al, 1997; Maehara et al, 1999; Saito et al, 1999)
and sporadic in fibroblasts (Naef et al, 1997). Positive TGF-b1
immunostaining was found to be related to invasion and
metastasis of gastric cancer (Nakamura et al, 1998; Maehara
et al, 1999). Finally, gastric cancer patients showed strongly
increased tissue TGF-b1 levels and, unexpectedly, reduced serum
TGF-b1 levels (Park et al, 1997).
Transforming growth factor-b1 is synthesised as an inactive
precursor, the large latent complex consisting of a TGF-b dimer,
the latency-associated protein (LAP) and latent TGF-b binding
protein (LTBP) for localisation and binding to the ECM (Mazzieri
et al, 2005). Before TGF-b1 can exert its biological effects, LAP and
LTBP have to be dissociated. This can occur by conformational
changes (Murphy-Ullrich and Poczatek, 2000; Annes et al, 2003;
Asano et al, 2006), proteolytic cleavage (Lyons et al, 1990; Taipale
et al, 1992; Dallas et al, 2002; Wang et al, 2006), irradiation
(Barcellos-Hoff et al, 1994; Ehrhart et al, 1997) or by an acid
environment (Jullien et al, 1989). The complex release mechanism
of TGF-b1 might implicate that high total TGF-b1 has no biological
consequences without the presence of appropriate activation
mechanisms in the tumour microenvironment. Therefore, measuring
TGF-b1 activity levels and the localisation in cancer could be more
informative regarding the state of cancer progression.
We studied cellular localisation and levels of active TGF-b1 and
the activation process in gastric cancer. We used an ELISA, which
specifically detects active TGF-b1, to examine endogenously active
as well as total (acid-activated) TGF-b1 levels in gastric cancer
tissue and showed cellular localisation of active TGF-b1b y
immunohistochemical staining. To study the activation process,
tissue levels of several proteases, putatively involved in the
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sactivation process, were determined and analysed for correlations
with TGF-b1 activity levels.
MATERIALS AND METHODS
Patient population
Fresh tissue specimens from a total of 51 patients (34 #,1 7~)
undergoing resection for primary gastric adenocarcinoma at the
department of Oncologic Surgery, Leiden University Medical
Centre, were collected as described before (Kubben et al, 2006).
Patient characteristics and clinicopathological parameters are
shown in Table 1. Tissue specimens were homogenised in Tris/
Tween-80 buffer, and protein concentrations were determined as
described previously (Sier et al, 1996).
ELISA for total and active TGF-b1
The levels of total and active TGF-b were measured using a human
TGF-b1 duo-set (DY240) with a substrate reagent pack (DY999)
according to the manufacturers’ instructions (both R&D Systems
Europe, Abingdon, UK). This ELISA specifically detects active
TGF-b1 and does not cross-react with other subtypes of TGF-b.
Total TGF-b1 levels were determined by acid activation (1 M
hydrochloric acid, 30min, room temperature) of the latent
TGF-b1 in the homogenate. Untreated and activated (30ml)
samples from the same homogenate were assayed in parallel.
Assays for urokinase, urokinase receptor, plasminogen
activator inhibitors, matrix metalloproteinases and tissue
inhibitors of matrix metalloproteinases
Total antigen levels of urokinase plasminogen activator (uPA),
plasminogen activator inhibitors (PAI-1 and -2), urokinase
plasminogen activator receptor, matrix metalloproteinases
(MMP-2, -7, -8, -9) and tissue inhibitors of matrix metalloprotei-
nases (TIMP-1 and -2) were determined using previously described
ELISAs (Ganesh et al, 1994; Sier et al, 1994; Hanemaaijer et al,
1998; Kubben et al, 2006). The bioactivity assays for uPA, MMP-2
and MMP-9 were performed as described before (Hanemaaijer
et al, 1998; Sier et al, 2000; Kubben et al, 2006).
Immunohistochemistry
Tissue samples from the same tumours as used for homogenates
were formalin fixed, dehydrated and embedded in paraffin. For
cryosections, unfixed tissue was embedded in OCT (Sakura Finetek
Europe BV, Zoeterwoude, The Netherlands) and snap-frozen in
liquid nitrogen. Paraffin sections (5mm) were deparaffinised,
blocked in 0.3% hydrogen peroxide (H2O2) in methanol for 20min
and rehydrated through graded alcohol. Antigen retrieval was
performed by boiling in a 0.01 M citrate solution (pH 6.0) for
10min in a microwave oven. After being rinsed in phosphate-
buffered saline (PBS), the sections were incubated with the
primary antibodies (in PBS/1% bovine serum albumin (BSA)):
mouse anti-pan-cytokeratin (1:1000, clone C11, Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), mouse anti-vimentin
(1:400, clone V9, Santa Cruz Biotechnologies), mouse anti-smooth
muscle actin (anti-SMA; 1:1000, clone ASM-1, Progen, Heidelberg,
Germany), mouse anti-TGF-b1 (1:1000, Anogen, Mississauga,
Ontario, Canada) or rabbit anti-phospho-smad-2 (p-smad-2;
1:1000, kindly provided by Professor/Dr P ten Dijke; Persson
et al, 1998) overnight at room temperature. After washing, the
sections were incubated with biotinylated goat anti-mouse (1:200)
or goat anti-rabbit (1:400, both Dako, Glostrup, Denmark)
secondary antibodies (in PBS/1% BSA) for 30min, followed by
washing and incubation with streptavidin–avidin–biotin com-
plex/HRP (Dako) for 30min. The brown colour was developed by
0.004% H2O2 (Merck, Darmstadt, Germany) and 0.05% diamino-
benzidine tetrahydrochloride (Sigma, Schnelldorf, Germany) in
0.01 M Tris–HCl pH 7.6 for 10min. The slides were counterstained
with Mayer’s haematoxylin (Merck) except for the p-smad-2
staining, which were shortly counterstained with methyl green,
diluted in 0.1 M sodium acetate buffer pH 4.2. Sections were
dehydrated and mounted in entellan (Merck).
Frozen sections (4mm) were fixated in ice-cold acetone (10min),
washed with PBS and incubated overnight (41C) with the primary
antibodies described below: anti-pan-cytokeratin (1:16000), anti-
vimentin (1:800), mouse anti-SMA (1:2000), rabbit anti-active
TGF-b1 (1:800, Promega, Madison, WI, USA) or phospho-smad-2
antibody (1:800). Further, the sections were treated as described
above and were counterstained with Mayer’s haematoxylin. Negative
control sections were included by omitting the primary antibodies.
Photomicrographs of representative sections were taken with a
Leica DMLB microscope equipped with a Leica DC500 camera.
Statistical analysis
Differences between normal and tumour values were calculated
using the Mann–Whitney U-test. For survival analyses, the
clinicopathological parameters were dichotomised as described
Table 1 Median levels
a of total and active TGF-b1 in gastric carcinomas
in relation to clinicopathological parameters
Active TGF-b1 Total TGF-b1
n Median Range P-value Median Range P-value
Age
o66 years 26 17.6 1.8–81.3 231.1 51.7–620.1
466 years 25 15.9 1.6–46.2 0.510 292.3 21.1–619.8 0.763
Laure ´n
Diffuse/
mixed
17 18.7 1.8–55.4 206.8 52.0–592.3
Intestinal 34 16.6 1.6–81.3 0.460 284.7 21.1–620.1 0.238
Differentiation
Well 21 15.5 1.8–55.4 214.2 52.0–620.0
Moderate/
poor
28 17.5 1.6–81.3 0.824 295.5 21.1–620.1 0.303
TNM
I 14 15.8 8.7–81.3 196.8 21.1–341.4
II–IV 37 18.1 1.6–71.0 0.688 292.8 62.2–620.1 0.010
Localization
Cardia 22 18.9 1.6–81.3 277.5 51.7–620.1
Rest 29 13.9 1.8–46.2 0.050 214.2 21.1–619.8 0.555
Diameter
o6cm 30 16.6 3.2–46.2 205.7 21.1–534.8
46cm 21 17.9 1.6–81.3 0.954 362.2 62.2–620.1 0.004
Invasion
Subserosa 34 19.1 1.6–81.3 221.3 21.1–620.1
Further 17 11.4 3.2–42.4 0.034 367.4 63.4–619.8 0.093
Inflammation
Non/mild 43 15.9 1.6–55.4 274.6 21.1–619.8
Severe 7 23.9 11.4–81.3 0.010 296.2 132.1–620.1 0.546
Status
b
Alive 17 13.9 1.8–46.2 209.5 21.1–385.0
Deceased 34 18.8 1.6–81.3 0.208 286.3 51.7–620.1 0.215
TGF-b1¼Transforming growth factor-b1; TNM, tumour node metastasis classifica-
tion.
aMedian and range in picogram per milligram protein.
bTumour-associated
death. Bold P-values are considered significant.
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sbefore (Sier et al, 1996). Cutoff values for TGF-b1 were optimised
using ROC analyses. Multivariate survival analyses were performed
with the Cox proportional hazards method by separately adding
variables to the dichotomised clinicopathological parameters.
Survival curves were constructed using the method of Kaplan
and Meier including log-rank tests. Differences were considered
significant when Pp0.05. The analyses were performed using the
SPSS statistical package (Release 12.01, SPSS Inc., Chicago, IL,
USA).
RESULTS
Tissue TGF-b1 levels and clinicopathological
characteristics
Active TGF-b1 was detectable in all 51 tumour homogenates with
concentrations of 1.6–81.3pgmg
 1 protein. Total TGF-b1 levels
ranged from 21.1 to 620.1pgmg
 1 protein. Active and total TGF-
b1 levels were significantly (Po0.0001) increased in gastric cancer
tissue compared with adjacent normal tissues (n¼20; Figure 1A
and B). ROC analyses revealed that total as well as active TGF-b1
were good diagnostic discriminators between normal and tumour
tissue with AUC values of, respectively, 0.91 (P¼0.03) and 0.82
(P¼0.05). Tumour levels of active TGF-b1 did not correlate
significantly with total levels (r¼0.255; P¼0.071, n¼51),
indicating that the amount of active form is not dependent on
the total TGF-b1 pool present. The correlation of TGF-b1 levels
with clinicopathological parameters is presented in Table 1. Active
TGF-b1 levels were significantly increased in tumours localised in
the cardia, in tumours with invasion limited to the subserosa and
in tumours with a high inflammation grade. Total TGF-b1 levels
were enhanced in tumours with high tumour node metastasis
(TNM) classification or large diameter.
Cellular localisation of active and total TGF-b1 in gastric
cancer
To determine the cellular localisation of active TGF-b1 in gastric
cancer, we stained frozen sections for active TGF-b1 (Figure 2A).
To confirm the staining being representative for TGF-b1 activity,
sections were also stained for phosphorylated smad-2 (p-smad-2),
indicating TGF-b signalling and therefore the presence of active
TGF-b (Massague et al, 2005; Blaney Davidson et al, 2006)
(Figure 2B). Nuclear localisation of p-smad-2 in myofibroblasts
and in malignant cells is shown in Figure 2 panels B1 and B2,
respectively.
Staining for both TGF-b1 and p-smad-2 was most pronounced
in vimentin-positive (Figure 2D) and SMA-positive (Figure 2E)
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Figure 1 Total and active TGF-b1 levels in tumour and corresponding normal tissue homogenates. Total (A) and active (B) TGF-b1 levels are significantly
upregulated in tumours (T) compared to corresponding normal (N) tissue (both Po0.0001).
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D C
B1 B2
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Figure 2 Cellular localisation of active TGF-b1 in gastric cancer. Immunohistochemical staining of gastric carcinomas (sequential frozen sections). Staining
pattern for active TGF-b1( A) corresponds to phospho-smad-2 staining (B). Inserts B1 and B2 show nuclear localisation (arrowheads) of p-smad-2 in the
myofibroblasts and malignant cells, respectively. As shown by staining for pan-cytokeratin (C, epithelial marker), vimentin (Vim, D, mesenchymal marker) and
SMA (E, smooth muscle/myofibroblast marker), TGF-b1 activity is observed in malignant cells and in Vimþ/SMAþ cells (myofibroblasts). Magnification
 200, -B1–B2  630.
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(Figure 2C). As, in our hands, staining for total TGF-b1 was not
detectable on frozen sections from gastric cancer specimens, we
stained 10 paraffin-embedded tissue sections from the above-
described patient group. Tumours showed strongly increased
epithelial and stromal staining for total TGF-b1 (Figure 3C)
compared to normal gastric mucosa (Figure 3A). Active TGF-b1,
represented by p-smad-2 staining (Figure 3D, staining for active
TGF-b1 was not applicable to paraffin sections), was increased in
both epithelial as well as stromal cells compared to little staining in
normal tissue (Figure 3B).
Figure 3E–G illustrates the association between active TGF-b1
ELISA data and the p-smad-2 immunohistochemical staining,
indicating TGF-b activity. Three carcinomas with decreasing active
TGF-b1 tissue levels (high, median and low) were stained for
p-smad-2 showing decreased nuclear staining for p-smad-2 in the
malignant cells and even stronger in the SMA-positive myofibro-
blasts (SMA, vimentin and pan-cytokeratin staining on sequential
sections, not shown).
Prognostic relevance tissue TGF-b1 levels
Kaplan–Meier survival curves, using tertiles (cutoff values o12.56;
12.56–21.28; 421.28pg TGF-b1mg
 1 protein; Figure 4A)
or quartiles (not shown), showed a stepwise correlation for
active and total TGF-b1 levels with tumour-associated survival.
Because of the small group size, the patients were dichotomised for
active and total TGF-b1 using ROC-based optimal cutoff values (15
(active) and 400 (total)pg TGF-b1mg
 1 protein, respectively) for
further analyses. High tumour levels of active and total TGF-b1
were significantly correlated with worse survival (log rank 4.88,
P¼0.027 and log rank 3.96, P¼0.047, respectively). Figure 4B
shows a Kaplan–Meier curve, presenting a combination of either
high total or high active TGF-b1, which resulted in a higher
ABCD
EFG
Figure 3 Total TGF-b and p-smad-2 staining on paraffin-embedded gastric cancer tissue sections. Staining on normal gastric mucosa shows some staining
for total TGF-b (A) and almost no staining for p-smad-2 (B, insert  400). Both are strongly increased in corresponding tumour tissue (C, total TGF-b1; D,
p-smad-2, insert  400). (E–G) p-smad 2 staining in three different gastric carcinomas with high (81.3pgmg
 1, E), median (21.1pgmg
 1, F) and low active
TGF-b1 levels (1.6pgmg
 1, G). A strong decrease in nuclear staining (inserts E–G, magnification  630, arrowheads indicate intense nuclear staining in
myofibroblasts in E) is observed especially in myofibroblasts (staining for pan-cytokeratin, vimentin and SMA on sequential sections, not shown).
Magnification  200.
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Figure 4 Kaplan–Meier survival analysis for tumour TGF-b1 tissue levels. (A) Kaplan–Meier analysis showed a stepwise decrease in survival for patients
divided in tertiles based on active TGF-b1 levels. L¼low (o12.56pg TGF-b1mg
 1 protein), I¼intermediate (12.56–21.28 TGF-b1mg
 1 protein),
H¼high (421.28TGF-b1mg
 1 protein), x/yw¼number of patients/number of patients deceased. (B) Kaplan–Meier analysis showed a significant shorter
survival for patients with either high active or high total TGF-b1 tissue levels. L¼low (active TGF-b1o15pg TGF-b1mg
 1 protein or total TGF-b
o400pgml
 1) and H¼high (active TGF-b1415pg TGF-b1mg
 1 protein or total TGF-b 4400pgml
 1).
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ssignificance value, confirming the independence of both para-
meters. To evaluate the validity of the chosen TGF-b1 cutoff values,
we used the same cutoff values again for the group including 29
more recently collected gastric cancer patients, where active TGF-
b1 kept its prognostic significance and the hazard ratio increased
(n¼80, HR 6.09, P¼0.014). The prognostic value of TGF-b1 was
further evaluated using Cox proportional hazard analyses (Table 2).
Particularly active TGF-b1 and the combined TGF-b1 levels were
statistically significantly correlated with survival. In multivariate
analysis with the clinicopathological parameters (Table 2), the
combined TGF-b1 level remained statistically significant in multi-
variate tests.
Proteolytic TGF-b1 activation
Because TGF-b1 is at least partly activated by proteolytic cleavage,
we evaluated the total and active TGF-b1 levels for correlations
with likely candidate proteinases involved in TGF-b1 activation
and with PAI-1, a presumed secondary marker of TGF-b1 activity,
in the gastric cancer homogenates (Table 3). Total TGF-b1 levels
showed significant correlation only with total MMP-2 antigen
levels, whereas active TGF-b1 levels only showed statistical
significant correlation with urokinase (uPA) activity, not with
total uPA protein levels.
DISCUSSION
Numerous studies have shown the involvement of TGF-b1i n
different types of cancer, including gastric, colorectal and breast
cancer (Naef et al, 1997; Nakamura et al, 1998; Maehara et al, 1999;
Saito et al, 1999; Desruisseau et al, 2006). Most of these studies
assessed tissue TGF-b1 levels by mRNA expression, immuno-
histochemistry or serum TGF-b1 levels, which give either less
information on the actual protein levels, are difficult to quantify or
do not reflect local effects. A recent study on TGF-b1 levels in
breast cancer tissue homogenates showed a significant relation of
increased tissue total TGF-b1 levels with disease-free survival
(Desruisseau et al, 2006). In the present study we observed a
similar relation of tissue total TGF-b1 level with survival of gastric
cancer patients. Although upregulation of TGF-b1 is common in
various types of cancer, it is not commonly regarded as a
prognostic factor for survival. This is probably due to the fact that
the release of the biologically active TGF-b1 from the latent
complex is crucial for the involvement of TGF-b1 in pathological
processes. Active TGF-b1 levels have hardly been studied because
of the absence of sensitive assays, which specifically detect active
TGF-b1 in the low concentrations observed in vivo. We optimised
an existing ELISA and were able to detect endogenous TGF-b1
levels (without acid activation) in all gastric cancer homogenates.
Furthermore, the localisation of active TGF-b1 in these cancers was
shown by immunohistochemical staining for active TGF-b1 and its
signalling molecule p-smad-2. In a sequential series of tumours
with decreasing active TGF-b1 levels (ELISA), we also observed
strongly decreasing nuclear staining pattern in the myofibroblasts.
Active TGF-b1 levels showed association with localisation,
invasion, inflammation and survival of gastric cancer patients.
As expected, the association of active TGF-b1 levels with survival
was indeed stronger compared to total TGF-b1 level. There was no
correlation between active and total TGF-b1 levels, implying that
the activation was not dependent of the total pool latent TGF-b1
present in the tumour microenvironment. As a consequence, total
TGF-b1 levels showed association with other parameters, that is
tumour diameter and TNM stage, whereas there was no association
of these parameters with active TGF-b1 levels.
Localisation of active TGF-b1 is observed in inflammatory- and
tumour cells and especially in tumour-associated myofibroblasts,
implying that increased levels of activated TGF-b1, more than
overall TGF-b1 levels, are associated with accumulation of
myofibroblasts in gastric cancer. Indeed, active TGF-b1 can induce
transdifferentiation from fibroblasts to myofibroblasts in the
tumour microenvironment, which show an increased expression
of various proteolytic enzymes including MMPs (Dwivedi et al,
2006). In turn, these proteases, including plasmin (George et al,
2005), MMP-2 (Wang et al, 2006), MMP-3 (Maeda et al, 2002) and
MMP-13 (D’Angelo et al, 2001), have been shown to be involved in
Table 2 Uni- and multivariate Cox’s proportional hazards analyses of total and active TGF-b1 levels in relation to tumour-associated survival of 51 gastric
cancer patients
Univariate Multivariate
Parameter HR CI 95% P-value HR CI 95% P-value
Age 1.258 0.637–2.484 0.509 1.584 0.662–2.716 0.240
Laure ´n classification 0.699 0.348–1.402 0.313 0.932 0.348–1.402 0.865
Differentiation 1.953 0.906–4.208 0.088 1.866 0.906–4.208 0.195
TNM classification 2.755 1.057–7.179 0.038 1.534 1.057–7.179 0.440
Tumour localization 2.379 1.092–5.180 0.029 1.916 1.092–5.180 0.151
Total TGF-b1 2.234 0.979–5.098 0.056 1.796 0.753–4.287 0.187
Active TGF-b1 2.339 1.065–5.138 0.034 2.125 0.934–4.836 0.072
High total/high active TGF-b1 3.108 1.240–7.788 0.016 2.763 1.061–7.199 0.037
Description of variables is shown in Table 1. Bold P-values are considered significant.
Table 3 Spearman’s correlations between the levels of total and active
TGF-b1 and various proteinases and proteinase inhibitors in 51 gastric
cancer homogenates
Active TGF-b1 Total TGF-b1
Assay q P-value q P-value
uPA ELISA 0.202 0.163 0.259 0.072
uPA BIA 0.284 0.048 0.125 0.394
uPAR ELISA 0.076 0.605 0.126 0.389
PAI-1 ELISA 0.195 0.185 0.198 0.176
PAI-2 ELISA  0.181 0.219  0.210 0.151
MMP-2 ELISA 0.219 0.149 0.296 0.048
MMP-2 BIA 0.253 0.111  0.060 0.709
MMP-7 ELISA  0.091 0.568 0.248 0.114
MMP-8 ELISA 0.717 0.240 0.111 0.449
MMP-9 ELISA 0.023 0.878 0.082 0.579
MMP-9 BIA 0.121 0.424 0.268 0.071
TIMP-1 ELISA  0.039 0.821 0.045 0.794
TIMP-2 ELISA  0.209 0.221  0.064 0.711
PAI¼plasminogen activator inhibitor; TIMP¼tissue inhibitor of matrix metallopro-
teinase; uPA¼urokinase plasminogen activator; uPAR¼urokinase plasminogen
activator receptor. ELISA, total antigen level; BIA, activity level. Bold P-values are
considered significant.
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between active TGF-b1 levels and urokinase activity, implying
plasmin, via urokinase-mediated plasminogen activation, as a
principal candidate of latent TGF-b1 activation. The investigated
MMPs showed no significant correlations with active TGF-b1
levels. For TIMP-1 and -2, we observed a weak negative correlation
with TGF-b1 activity, also observed in vivo in a recent study
(Dasgupta et al, 2006). Total TGF-b1 levels only correlated
significantly with MMP-2 levels in homogenates. Immunohisto-
chemistry showed TGF-b1 activity present in different cell types,
probably with different activators in the tumour microenviron-
ment. This explains why in a homogenate it is unlikely that a
strong significant association with one specific MMP will be
observed.
In conclusion, we have shown that total and active TGF-b1 levels
are increased in gastric tumour tissue and that both are of
prognostic relevance in gastric cancer. Active tissue TGF-b1 levels
showed association with clinicopathological parameters and with
uPA activity, indicating a possible role for plasmin in TGF-b1
activation in gastric cancer. Immunohistochemical studies showed
strong expression of active TGF-b1 in the myofibroblast popula-
tion. We propose that increased proteinase activity in the tumour
microenvironment leads to increased ECM-bound latent TGF-b1
activation, resulting in transformation of resident fibroblasts to
tumour promoting myofibroblasts. Further studies on a larger
group of patients should be performed to establish the prognostic
value of active tissue TGF-b1 levels in gastric cancer and further
elucidate the mechanism of latent TGF-b1 activation.
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